Ascendis Health (JSE:ASC) Research & Development: R0 Mil (TTM As of Jun. 2023)


JSE:ASC Ascendis Health Ltd JSE:ASC
11 GF Score
Price R0.92
View Full Analysis

What is Ascendis Health Research & Development?

Ascendis Health JSE:ASC 11 Research & Development is R0 Mil as of Jun. 2023. GuruFocus rates JSE:ASC with a GF Score™ of 11/100.

Research & Development is the aggregate amount of research and development expenses during the year. Ascendis Health's Research & Development for the six months ended in Jun. 2023 was R0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 was R0 Mil.

Ascendis Health  (JSE:ASC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Ascendis Health Research & Development Related Terms

Ascendis Health Research & Development Historical Data

* Premium members only.

The historical data trend for Ascendis Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Health Research & Development Chart

Ascendis Health Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ascendis Health Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
JSE:ASC
11GF Score
Ascendis Health Ltd JSE:ASC
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was R0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of R0 Mil mean?
Ascendis Health (JSE:ASC) has a Research & Development of R0 Mil as of Jun. 2023. Research and development expense is the total cost for research and development activities. View historical data on Ascendis Health and its competitors.
Is Ascendis Health's Research & Development too high?
Ascendis Health's current Research & Development is R0 Mil. Overall, Ascendis Health has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Health's Research & Development compare to PHBI and GCAN?
Ascendis Health's Research & Development of R0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Ascendis Health and its competitors. Ascendis Health's current Research & Development is R0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Health stock overvalued right now?
Ascendis Health (JSE:ASC) has a current Research & Development of R0 Mil. The current Research & Development is R0 Mil. Ascendis Health's overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Ascendis Health (JSE:ASC), the current Research & Development is R0 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Health Business Description

Address 1 Carey Street, Wynberg, Sandton, GT, ZAF, 2090
Ascendis Health Ltd is a health and wellness investment holding Company that holds investments in a number of companies that market and distribute a portfolio of brands, products, and medical devices. The company operates in two segments: i) Consumer Health (wellness, health supplements, speciality ingredients and compounded medicines) and ii) Medical Devices (distributor of medical devices, in vitro diagnostic products and orthopaedic equipment). The company generates the majority of its revenue from the Medical Devices segment.
11GF Score

Get the complete analysis for JSE:ASC

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R0.92
Price